Title:Maximizing Treatment Options for IBD through Drug Repurposing
Volume: 30
Issue: 32
Author(s): Amir Hossein Barjasteh, Abdulridha Mohammed Al-Asady, Hanieh Latifi, Souad Al Okla, Nasser Al-Nazwani, Amir Avan, Majid Khazaei, Mikhail Ryzhikov, Hanieh Nadi-Yazdi and Seyed Mahdi Hassanian*
Affiliation:
- Metabolic Syndrome Research Center, Mashhad University
of Medical Sciences, Mashhad, Iran
- Department of Clinical Biochemistry,
Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords:
Inflammatory bowel disease, ulcerative colitis, drug repurposing, inflammation, Crohn's disease, small molecule therapies.
Abstract: Chronic inflammation characterizes Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease
(CD) and Ulcerative Colitis (UC). Despite modest activity of disease in most UC patients, exacerbations
occur, especially in those with severe symptoms, necessitating interventions, like colectomy. Current treatments
for IBD, predominantly small molecule therapies, impose significant economic burdens. Drug repurposing
offers a cost-effective alternative, leveraging existing drugs for novel therapeutic applications. This approach
capitalizes on shared molecular pathways across diseases, accelerating therapeutic discovery while minimizing
costs and risks. This article provides an overview of IBD and explores drug repurposing as a promising
avenue for more effective and affordable treatments. Through computational and animal studies, potential
drug candidates are categorized, offering insights into IBD pathogenesis and treatment strategies.
